

## Department of Internal Medicine Division of Cardiology

Michihiro Yoshimura, Professor  
Ikuo Taniguchi, Professor  
Masayuki Taniguchi, Associate Professor  
Teiichi Yamane, Associate Professor  
Hideki Sasaki, Associate Professor  
Takahiro Shibata, Assistant Professor  
Atsushi Seo, Assistant Professor  
Kimiaki Komukai, Assistant Professor

Mitsuyuki Shimizu, Professor  
Katsunori Ikewaki, Associate Professor  
Shingo Seki, Associate Professor  
Kenichi Hongo, Associate Professor  
Satoru Yoshida, Assistant Professor  
Naofumi Aoyama, Assistant Professor  
Makoto Kawai, Assistant Professor  
Toshio Hasuda, Assistant Professor

### General Summary

We are actively engaged in research activities associated with daily clinical practices, including large-scale clinical trials and multicenter trials. We have been participating in and cooperating with several large-scale clinical trials, notably the Japanese Investigation of Kinetic Evaluation in Hypertensive Event And Remodeling Treatment (JIKEI HEART) study, the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study, the Assessment of  $\beta$ -Blocker Treatment in Japanese Patients with Chronic Heart Failure (J-CHF) study, the Pitavastatin hEARt faiLure (PEARL) study, and the Combination of OLMesartan and Calcium channel blocker or diuretics in high risk elderly hypertensive patients Study (COLM) study. The JIKEI HEART Study, is a voluntary physician-oriented study initiated by our chairperson. It is the first clinical-outcome cardiology study in Japan to demonstrate that an angiotensin II receptor blocker administration significantly reduces risks. The study results were reported in *The Lancet* (Mochizuki S, et al. Lancet 2007; 369: 1431-9).

### Research Activities

#### *Clinical research*

##### 1. Ischemic heart disease

Individual clinical research sections have been compiling subject data, such as risk factors and lesional morphology collected through catheterization tests or treatments, into a database that can be used to compare risk factors and prognosis for ischemic heart diseases, such as cardiomyopathy. Furthermore, we have been carefully examining treatments, mainly those using drug-eluting stents, and diagnoses of vasospasm, which is intimately associated with the development of ischemic heart diseases. We have also been participating in nationwide clinical research activities. Coronary artery computed tomographic scanning using dual-source computed tomography started this May, and we are accumulating visualization exposures at a rate of 950 cases per year. Temporal resolution capacity of our current system is greater than that of our former one, enabling us to provide more accurate diagnoses and detailed examinations for cases of arrhythmia or high cardiac pulsation.

## 2. Heart failure

We have been examining the serum level of brain natriuretic protein as an indicator of heart failure and investigating reference values that can be used in clinical practice. Also, we are now making detailed examinations of the pathological condition of heart failure, both before and after hospital admission, to obtain clinical data for establishing new indicators.

## 3. Arrhythmia

We used catheter ablation to treat 232 cases of atrial fibrillation this year. In clinical research, we published papers on the following topics: 1) examining the usefulness of pulmonary vein antral isolation using a potential indicator, and 2) suppression of reentry into the signaling pathway by annihilation of reentry into ATP signaling after pulmonary vein antral isolation.

## 4. Lipid metabolism

With regard to human lipoprotein metabolic research using a stable isotope, we collaborated with Kanazawa University to perform tracer experiments on patients with autosomal recessive hypercholesterolemia, which is an extremely rare condition. Additionally, we examined the effect of ezetimibe, an inhibitor of cholesterol absorption from the small intestine, on lipoprotein metabolism and are now analyzing the data.

### *Basic research activities*

Basic research activities include domestic and international exchanges of graduate students in basic or clinical courses and the publication of the results of their studies. For research into the cause of atrial fibrillation, we are now observing changes in the expression of connexin, which controls intracellular signal transduction, and decreases in cardiac function/pressure load in the Dahl model of hypertension-induced heart failure. We are also evaluating the localization of proteins, such as zona occludens 1, associated with connexin. In cardiomyocyte physiology, we are examining the physiological and pathophysiological regulatory mechanisms of myocardial contraction and relaxation, at both molecular biological and physiological levels. We are also examining a new signal transduction pathway and its effects on alpha-adrenergic receptor stimulation in the L-type Ca channel of rat myocardium, the effects of beta-adrenergic receptor stimulation on the sarcoplasmic reticulum function, and Ca handling in the cardiomyocytes of mice with dilated cardiomyopathy induced by troponin T mutation. In myocardial metabolism, we have been evaluating the relationship between ischemic reperfusion injury and intracellular ionic handling using isolated perfused hearts from a mouse model of type 2 diabetes.

### **Publications**

**Arantes L, Matsuo S, Lim KT, Knecht S, Jais P, Haissaguerre M.** Left atrial appendage activity mimicking an epsilon wave on the surface electrocardiogram. *J Cardiovasc Electrophysiol* 2007; **18**: 1114-5.

**Arantes LB, Klein GJ, Jais P, Matsuo S, Lim KT, Knecht S, Haissaguerre M.** Atrial tachycardia

transition during ablation of persistent atrial fibrillation: what is the mechanism? *J Cardiovasc Electrophysiol* 2007; **18**: 1109-11.

**Fukunaga T<sup>1</sup>, Soejima H<sup>1,3</sup>, Irie A<sup>1</sup>, Sugamura K<sup>1</sup>, Oe Y<sup>1</sup>, Tanaka T<sup>1</sup>, Nagayoshi Y<sup>1</sup>, Kaikita K<sup>1</sup>, Sugiyama S<sup>1</sup>, Yoshimura M<sup>1</sup>, Nishimura Y<sup>2</sup>, Ogawa H<sup>1</sup>** (<sup>1</sup>*Cardiovasc Med*, <sup>2</sup>*Immunogenet*,

- Grad Sch Med Sci** <sup>2</sup>**Health Care Center, Kumamoto Univ.** Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2007; **100**: 483-8.
- Fukunaga T<sup>1</sup>, Soejima H<sup>1,3</sup>, Irie A<sup>2</sup>, Sugamura K<sup>1</sup>, Oe Y<sup>1</sup>, Tanaka T<sup>1</sup>, Kojima S<sup>1</sup>, Sakamoto T<sup>1</sup>, Yoshimura M, Nishimura Y<sup>2</sup>, Ogawa H<sup>1</sup>** (*Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ, <sup>2</sup>Dept Intern Med Mol Sci, Grad Sch Med, Osaka Univ, <sup>3</sup>Dept Cardiovasc Med, Kumamoto Natl Hosp, Div Cardiol, Fukuoka Tokushukai Hosp*). Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. *Atherosclerosis* 2007; **194**: 204-13.
- Komukai K, Ogawa T, Yagi H, Date T, Suzuki K, Sakamoto H, Miyazaki H, Takatsuka H, Shibayama K, Ogawa K, Kanzaki Y, Kosuga T, Kawai M, Hongo K, Yoshida S, Taniguchi I, Mochizuki S.** Renal insufficiency is related to painless myocardial infarction. *Circ J* 2007; **71**: 1366-9.
- Komukai K, Ogawa T, Yagi H, Date T, Suzuki K, Sakamoto H, Miyazaki H, Takatsuka H, Shibayama K, Ogawa K, Kanzaki Y, Kosuga T, Kawai M, Hongo K, Yoshida S, Taniguchi I, Mochizuki S.** Renal insufficiency is related to painless myocardial infarction. *Circ J* 2007; **71**: 1366-9.
- Kronenberg F<sup>1</sup>, Ikewaki K, Schaefer JR (Marburg), König P<sup>1</sup>, Dieplinger H<sup>1</sup> (Innsbruck).** Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology? *Semin Dial* 2007; **20**: 554-60.
- Lim KT, Jaïs P, O'Neill MD, Knecht S, Matsuo S, Arantes L, Kodali S, Hocini M, Klein G, Clémenty J, Haïssaguerre M.** Cycle length dependent block in the mitral-pulmonary vein isthmus. *Pacing Clin Electrophysiol* 2007; **30**: 1174-6.
- Matsukawa M<sup>1</sup>, Kaikita K<sup>1</sup>, Soejima K<sup>2</sup>, Fuchigami S<sup>1</sup>, Nakamura Y<sup>1</sup>, Honda T<sup>1</sup>, Tsujita K<sup>1</sup>, Nagayoshi Y<sup>1</sup>, Kojima S<sup>1</sup>, Shimomura H<sup>1</sup>, Sugiyama S<sup>1</sup>, Fujimoto K<sup>4</sup>, Yoshimura M, Nakagaki T<sup>2</sup>, Ogawa H<sup>1</sup>** (*Dept Cardiovasc Med, Graduate Sch Med Sci, Kumamoto Univ, <sup>2</sup>First Res Dept, Chemo-Sero-Ther Res Inst, <sup>3</sup>Dept Cardiovasc Med, Fukuoka Tokushukai Med Cent, <sup>4</sup>Dept Cardiovasc Med, Natl Hosp Organ Kumamoto Med Cent*). Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. *Am J Cardiol* 2007; **100**: 758-63.
- Matsuo S, Jaïs P, Hocini M, O'Neill MD, Kodali S, Arantes L, Knecht S, Lim KT, Klein GJ, Clémenty J, Haïssaguerre M.** Hôpital Cardiologique du Haut-Lévêque, Bordeaux. Left atrial mitral isthmus block after radiofrequency ablation? *J Cardiovasc Electrophysiol* 2007; **18**: 676-7.
- Matsuo S, Lim KT, Haïssaguerre M.** Hôpital Cardiologique du Haut-Lévêque, Bordeaux: ablation of chronic atrial fibrillation. *Heart Rhythm* 2007; **4**: 1461-3.
- Matsuo S, Veenhuyzen GD, Arantes L, Lim KT, Jaïs P, Haïssaguerre M.** Hôpital Cardiologique du Haut-Lévêque, Bordeaux. Conversion of atrial fibrillation during pulmonary vein isolation: time to stop and have a rest? *J Cardiovasc*
- Grad Sch Med Sci** <sup>2</sup>**Health Care Center, Kumamoto Univ.** Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2007; **100**: 483-8.
- Fukunaga T<sup>1</sup>, Soejima H<sup>1,3</sup>, Irie A<sup>2</sup>, Sugamura K<sup>1</sup>, Oe Y<sup>1</sup>, Tanaka T<sup>1</sup>, Kojima S<sup>1</sup>, Sakamoto T<sup>1</sup>, Yoshimura M, Nishimura Y<sup>2</sup>, Ogawa H<sup>1</sup>** (*Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ, <sup>2</sup>Dept Intern Med Mol Sci, Grad Sch Med, Osaka Univ, <sup>3</sup>Dept Cardiovasc Med, Kumamoto Natl Hosp, Div Cardiol, Fukuoka Tokushukai Hosp*). Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure. *Heart Vessels* 2007; **22**: 345-52.
- Haïssaguerre M, Hocini M, Takahashi Y, O'Neill MD, Pernat A, Sanders P, Jonsson A, Rotter M, Sacher F, Rostock T, Matsuo S, Arantés L, Teng Lim K, Knecht S, Bordachar P, Laborde J, Jaïs P, Klein G, Clémenty J.** Impact of catheter ablation of the coronary sinus on paroxysmal or persistent atrial fibrillation. *J Cardiovasc Electrophysiol* 2007; **18**: 378-86.
- Haïssaguerre M, Lim KT, Jacquemet V, Rotter M, Dang L, Hocini M, Matsuo S, Knecht S, Jaïs P, Virag N.** Atrial fibrillatory cycle length: computer simulation and potential clinical importance. *Europace* 2007; **9**(Suppl 6): vi64-70.
- Itoh T<sup>1</sup>, Mizuno Y<sup>1</sup>, Harada E<sup>1</sup>, Yoshimura M, Ogawa H<sup>2</sup>, Yasue H<sup>1</sup>** (*Div Cardiol, Kumamoto Kino Hosp, Kumamoto Aging Res Inst, <sup>2</sup>Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ*). Coronary spasm is associated with chronic low-grade inflammation. *Circ J* 2007; **71**: 1074-8.
- Jaïs P, Hocini M, O'Neill MD, Klein GJ, Knecht S, Matsuo S, Arantes L, Kodali S, Clémenty J, Haïssaguerre M.** How to perform linear lesions. *Heart Rhythm* 2007; **4**: 803-9.
- Knecht S, Jaïs P, Lim KT, Veenhuyzen GD, Matsuo S, Haïssaguerre M.** Slow conduction of the Vein of Marshall in the context of permanent atrial fibrillation ablation. *J Cardiovasc Electrophysiol* 2007; **18**: 1004-5.
- Knecht S, Matsuo S, O'Neill MD, Kodali S, Arantes L, Lim KT, Hocini M, Jaïs P, Klein G, Clémenty J, Haïssaguerre M.** Atrial arrhythmia after a first atrial fibrillation ablation: what is the mechanism? *J Cardiovasc Electrophysiol* 2007; **18**: 780-2.
- Knecht S, O'Neill MD, Matsuo S, Lim KT, Arantes L, Derval N, Klein GJ, Hocini M, Jaïs P, Clémenty J, Haïssaguerre M.** Focal arrhythmia confined within the coronary sinus and maintaining atrial fibrillation. *J Cardiovasc Electrophysiol* 2007; **18**: 1140-6.
- Knecht S, Wright M, Sacher F, Lim KT, Matsuo S, O'Neill MD, Hocini M, Jaïs P, Clémenty J, Haïssaguerre M.** Relationship between perimetal and peritricuspid conduction times. *Heart Rhythm* 2008; **5**: 400-5.
- Kojima S<sup>1</sup>, Funahashi T<sup>2</sup>, Otsuka F<sup>1</sup>, Maruyoshi H<sup>1</sup>, Yamashita T<sup>1</sup>, Kajiwara I<sup>3</sup>, Shimomura H<sup>4</sup>**

- Electrophysiol* 2007; **18**: 889-91.
- Matsuo S, Yamane T, Date T, Inada K, Kanzaki Y, Tokuda M, Shibayama K, Miyanaga S, Miyazaki H, Sugimoto K, Mochizuki S.** Reduction of AF recurrence after pulmonary vein isolation by eliminating ATP-induced transient venous re-conduction. *J Cardiovasc Electrophysiol* 2007; **18**: 704-8.
- Matsuo S, Yamane T, Date T, Inada K, Kanzaki Y, Tokuda M, Shibayama K, Miyanaga S, Miyazaki H, Sugimoto K, Mochizuki S.** Jikei University School of Medicine, Tokyo reduction of AF recurrence after pulmonary vein isolation by eliminating ATP-induced transient venous re-conduction. *J Cardiovasc Electrophysiol* 2007; **18**: 704-8.
- Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki , Okazaki F, Taniguchi M, Yoshida S, Tajima N, for the Jikei Heart Study group.** Valsartan in Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study) a randomized, open-label, blinded endpoint morbidity-mortality study. *Lancet* 2007; **369**: 1431-9.
- Morimoto S, Izumi T, Sakurai T, Komukai K, Kawai M, Yagi H, Hongo K, Shibata T, Mochizuki S.** Pulmonary embolism and deep vein thrombosis complicating acute aortic dissection during medical treatment. *Intern Med* 2007; **46**: 477-80.
- Mutoh M, Ishikawa T, Hasuda T, Okada H, Endo A, Miyanaga S, Higashitani M, Nakano Y, Kubota T, Nakata K, Nagoshi T, Hayashi M, Sakamoto H, Oota M, Imai K, Mochizuki S.** Predictors of target lesion revascularization and documented stent thrombosis beyond 30 days after sirolimus-eluting stent implantation:retrospective analysis in consecutive 1,070 angiographic follow-up lesions. *Circ J* 2007; **71**: 1328-31.
- Nakada Y, Kurosawa H, Tohyama J, Inoue Y, Ikewaki K.** Increased remnant lipoprotein in patients with coronary artery disease: evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). *J Atheroscler Thromb* 2007; **14**: 56-64.
- Nishijima T<sup>1</sup>, Nakayama M<sup>1</sup>, Yoshimura M, Abe K<sup>1</sup>, Yamamuro M<sup>1</sup>, Suzuki S<sup>1</sup>, Shono M<sup>1</sup>, Sugiyama S<sup>1</sup>, Saito Y<sup>3</sup>, Miyamoto Y<sup>4</sup>, Nakao K<sup>5</sup>, Yasue H<sup>2</sup>, Ogawa H<sup>1</sup>** (<sup>1</sup>Dept Cardiovasc Med, Graduate Sch Med Sci, Kumamoto Univ, <sup>2</sup>Div Cardiol, Kumamoto Aging Res Inst, <sup>3</sup>First Dept Intern Med, Nara Med Univ, <sup>4</sup>Div Atherosclerosis Diabetes, Natl Cardiovasc Center Suita, Osaka, <sup>5</sup>Dept Med Clin Sci, Kyoto Univ Graduate Sch Med, Sakyou-ku). The endothelial nitric oxide synthase gene -786T/C polymorphism is a predictive factor for reattacks of coronary spasm. *Pharmacogenet Genomics* 2007; **17**: 581-7.
- Nishiyama K<sup>1</sup>, Takaji K<sup>2</sup>, Uchijima Y<sup>1</sup>, Kurihara Y<sup>1</sup>, Asano T<sup>3</sup>, Yoshimura M, Ogawa H<sup>1</sup>, Kurihara H<sup>1</sup>** (<sup>1</sup>Dept Physiol Chem Metab, Grad Sch Med, <sup>2</sup>Univ Tokyo, <sup>3</sup>Dept Cardiovasc Surg, Grad Sch Med Sci, Kumamoto Univ, <sup>3</sup>Dept of Biomed Chem, Hiroshima Univ Graduate Sch Biomed Sci, <sup>4</sup>Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ). Protein kinase A-regulated nucleocytoplasmic shuttling of Id1 during angiogenesis. *J Biol Chem* 2007; **282**: 17200-9.
- Ogawa K, Ikewaki K, Taniguchi I, Takatsuka H, Mori C, Sasaki H, Okazaki F, Shimizu M, Mochizuki S.** Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. *Int Heart J* 2007; **48**: 337-45.
- O'Neill MD, Hocini M, Matsuo S, Haissaguerre M.** Twin perimtrial atrial flutters with alternating cycle lengths. *J Cardiovasc Electrophysiol* 2007; **18**: 455-6.
- Otsuka F<sup>1</sup>, Sugiyama S<sup>1</sup>, Kojima S<sup>1</sup>, Maruyoshi H<sup>1</sup>, Funahashi T<sup>2</sup>, Sakamoto T<sup>1</sup>, Yoshimura M, Kimura K<sup>3</sup>, Umemura S<sup>3</sup>, Ogawa H<sup>1</sup>** (<sup>1</sup>Dept Cardiovasc Med, Graduate Sch Med Sci, Kumamoto Univ, <sup>2</sup>Dept Intern Med Mol Sci, Graduate Sch Med, Osaka Univ, <sup>3</sup>Div Cardiol, Yokohama City Univ Med Cent).
- Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. *Circ J* 2007; **71**: 1703-9.
- Sakamoto T<sup>1</sup>, Shintomi Y<sup>1</sup>, Yoshimura M, Ogawa H<sup>1</sup>** (<sup>1</sup>Dept Cardiovasc Med, Kumamoto Univ Hosp). Successful treatment of refractory angina pectoris due to multivessel coronary spasm with valsartan. *Intern Med* 2007; **46**: 1425-9.
- Sasaki H, Ogawa K, Shimizu M, Mori C, Takatsuka H, Okazaki F, Kawai M, Taniguchi I, Mochizuki S.** The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats. *Int Heart J* 2007; **48**: 623-35.
- Sasaki H, Shimizu M, Ogawa K, Okazaki F, Taniguchi M, Taniguchi I, Mochizuki S.** Brief ischemia-reperfusion performed after prolonged ischemia (ischemic postconditioning) can terminate reperfusion arrhythmias with no reduction of cardiac function in rats. *Int Heart J* 2007; **48**: 205-13.
- Sasaki H, Shimizu M, Ogawa K, Okazaki F, Mizokami T, Kusaka M, Uehara Y, Taniguchi I, Mochizuki S.** Defect images in stress thallium-201 myocardial scintigraphy in patients with complete left bundle branch block: comparison of exercise stress and pharmacological stress. *J Cardiol* 2007; **49**: 179-85.
- Shikata C, Sekikawa T, Kimura N, Seki S, Takeda N.** Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. *Exp Clin Cardiol* 2007; **12**: 33-6.
- Shimasaki Y<sup>1</sup>, Saito Y<sup>2</sup>, Yoshimura M, Kamitani S<sup>3</sup>, Miyamoto Y<sup>3</sup>, Masuda I<sup>3</sup>, Nakayama M<sup>1</sup>, Mizuno Y<sup>4</sup>, Ogawa H<sup>1</sup>, Yasue H<sup>4</sup>, Nakao K<sup>3</sup>** (<sup>1</sup>Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ, <sup>2</sup>First Dept Intern Med, Nara Med

**Univ, <sup>3</sup>Dept Med Clin Sci, Kyoto Univ Grad Sch Med, <sup>4</sup>Div Cardiol, Kumamoto Kino Hosp, Kumamoto Aging Res Inst.** The effects of long-term smoking on endothelial nitric oxide synthase mRNA expression in human platelets as detected with real-time quantitative RT-PCR. *Clin Appl Thromb Hemost* 2007; **13**: 43-51.

**Shono M<sup>1</sup>, Yoshimura M, Nakayama M<sup>1</sup>, Yamamuro M<sup>1</sup>, Abe K, Suzuki S<sup>1</sup>, Mizuno Y<sup>2</sup>, Sugiyama S<sup>1</sup>, Saito Y (First Dept Intern Med, Nara Med Univ Nara), Nakao K (Dept Med Clin Sci, Kyoto Univ Graduate Sch Med), Yasue H<sup>2</sup> (<sup>2</sup>Div Cardiol, Kumamoto Aging Res Inst), Ogawa H<sup>1</sup> (<sup>1</sup>Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto Univ).** Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. *Circ J* 2007; **71**: 1040-6.

**Soejima H<sup>1,3</sup>, Irie A<sup>2</sup>, Fukunaga T<sup>1</sup>, Oe Y<sup>1</sup>, Kojima S<sup>1</sup>, Kaikita K<sup>1</sup>, Kawano H<sup>1</sup>, Sugiyama S<sup>1</sup>, Yoshimura M<sup>1</sup>, Kishikawa H<sup>3</sup>, Nishimura Y<sup>2</sup>, Ogawa H<sup>1</sup> (Dept <sup>1</sup>Cardiovasc Med, <sup>2</sup>Immunogenet, Grad Sch Med Sci <sup>3</sup>Health Care Cent, Kumamoto Univ).** Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. *Circ J* 2007; **71**: 1879-84.

**Suzuki S, Yoshimura M, Nakayama M, Abe K, Yamamuro M, Nagayoshi Y, Kojima S, Kaikita K, Sugiyama S, Yasue H<sup>2</sup>, Ogawa H** (<sup>1</sup>Dept Cardiovasc Med Graduate Sch Med Sci, Kumamoto Univ, <sup>2</sup>Div Cardiol, Kumamoto Aging Res Inst). A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis. *Pharmacogenet Genomics* 2007; **17**: 919-30.

**Takahashi Y, O'Neill MD, Hocini M, Dubois R, Matsuo S, Knecht S, Mahapatra S, Lim KT, Jaïs P, Jonsson A, Sacher F, Sanders P, Rostock T,**

**Bordachar P, Clémenty J, Klein GJ, Haïssaguerre M.** Characterization of electrograms associated with termination of chronic atrial fibrillation by catheter ablation. *J Am Coll Cardiol* 2008; **51**: 1003-10.

**Yamane T, Date T, Kanzaki Y, Inada K, Matsuo S, Shibayama K, Miyanaga S, Miyazaki H, Sugimoto K, Mochizuki S.** Segmental plmonary vein antrum isolation using the large-size lasso catheter in patients with atrial fibrillation. *Circ J* 2007; **71**: 753-60.

**Yonemori K, Kunitoh H, Tsuta K, Tamura T, Arai Y, Shimada Y, Fujiwara Y, Sasajima Y, Asamura H, Tamura T.** Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patient. *Med Oncol* 2007; **24**: 425-30.

## Reviews

**Lim KT, Matsuo S, O'Neill MD, Knecht S, Arantes L, Derval N, Jaïs P, Hocini M, Clémenty J, Haïssaguerre M.** Catheter ablation of persistent and permanent atrial fibrillation: Bordeaux experience. *Expert Rev Cardiovasc Ther* 2007; **5**: 655-62.

**Nakayama M<sup>1</sup>, Kudoh T<sup>1</sup>, Kaikita K<sup>1</sup>, Yoshimura M, Oshima S (Div Cardiol Kumamoto Cent Hosp), Miyamoto Y (Div Atherosclerosis Diabetes, Natl Cardiovasc Center), Takeya M (Dept Cell Pathol, Graduate Sch Med Sci, Kumamoto Univ), Ogawa H<sup>1</sup> (<sup>1</sup>Dept Cardiovasc Med, Graduate Sch Med Sci, Kumamoto Univ).** Class A macrophage scavenger receptor gene expression levels in peripheral blood mononuclear cells specifically increase in patients with acute coronary syndrome. *Atherosclerosis* 2007 Epub ahead of print.